Back to School: How biopharma can reboot drug development. Access exclusive analysis here

igeneon: The self-help approach

Many companies developing cancer therapies deal primarily with the remission of solid tumors. Austrian cancer play igeneon AG instead focuses on disseminated tumor cells that survive standard therapies and, often several years later, lead to metastases. While its products are designed as complementary to conventional treatments, the company believes mobilizing the body's defenses is the most innovative and promising approach in fighting metastasis, because once mobilized, the immune system should provide long-lasting protection

Read the full 736 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers